Door Prof. Dr. Hans Bijlsma wordt ingegaan op de balans tussen effectiviteit en veiligheid bij Glucocorticoїden (GC): leiden GC altijd tot botverlies, of kan het ontstekingsremmend effect sterker zijn dan de direct negatieve effecten op het bot? Zijn de bijwerkingen dosis-afhankelijk? Hoe kijken patiënten tegen bijwerkingen aan? Zijn er nieuwe medicamenten in aantocht met minder bijwerkingen?
This presentation by Gavin Giovannoni looks at the new treatment paradigm for MS. It includes: arguments for early treatment in multiple sclerosis, the effect of MS on quality of life and whether highly-effective treatments stabilise MS.
It was presented at the MS Trust Annual Conference in November 2013.
PANEL DISCUSSION ON ENDOMETRIOSIS IN ADOLESCENTS (2018 )Lifecare Centre
PANEL DISCUSSION ON ENDOMETRIOSIS IN ADOLESCENTS (2018 ) MODERATOR
DR SHARDA JAIN
DR ILA GUPTA
DR DIPTI NABH
panelist
UMA RAI
RAJ BOKARIA
JYOTI AGARWAL
JYOTI BHASKER
RENU CHAWLA
DIPTI NABH
VANDANA GUPTA
Denosumab is a potent monoclonal antibody which inactivates
the RANK ligand. Inactivation of RANK ligand leads to the
inhibition of osteoclast activity and maturation which decreases
bone resorption. Denosumab is a potent antiresorptive that has been shown to dramatically suppress bone turnover markers, maintain bone mineral density, and prevent fractures
Denosumab is a potent monoclonal antibody which inactivates
the RANK ligand. Inactivation of RANK ligand leads to the
inhibition of osteoclast activity and maturation which decreases
bone resorption. Denosumab is a potent antiresorptive that has been shown to dramatically suppress bone turnover markers, maintain bone mineral density, and prevent fractures
IWO Meeting 1 November 2023 - Stopping with Denosumab and Romosozumab, basic mechanisms and clinical aspects door Prof. dr. S. Ferrari, Geneva, Switzerland. (Engelstalige lezing)
Door Prof. Dr. Hans Bijlsma wordt ingegaan op de balans tussen effectiviteit en veiligheid bij Glucocorticoїden (GC): leiden GC altijd tot botverlies, of kan het ontstekingsremmend effect sterker zijn dan de direct negatieve effecten op het bot? Zijn de bijwerkingen dosis-afhankelijk? Hoe kijken patiënten tegen bijwerkingen aan? Zijn er nieuwe medicamenten in aantocht met minder bijwerkingen?
This presentation by Gavin Giovannoni looks at the new treatment paradigm for MS. It includes: arguments for early treatment in multiple sclerosis, the effect of MS on quality of life and whether highly-effective treatments stabilise MS.
It was presented at the MS Trust Annual Conference in November 2013.
PANEL DISCUSSION ON ENDOMETRIOSIS IN ADOLESCENTS (2018 )Lifecare Centre
PANEL DISCUSSION ON ENDOMETRIOSIS IN ADOLESCENTS (2018 ) MODERATOR
DR SHARDA JAIN
DR ILA GUPTA
DR DIPTI NABH
panelist
UMA RAI
RAJ BOKARIA
JYOTI AGARWAL
JYOTI BHASKER
RENU CHAWLA
DIPTI NABH
VANDANA GUPTA
Denosumab is a potent monoclonal antibody which inactivates
the RANK ligand. Inactivation of RANK ligand leads to the
inhibition of osteoclast activity and maturation which decreases
bone resorption. Denosumab is a potent antiresorptive that has been shown to dramatically suppress bone turnover markers, maintain bone mineral density, and prevent fractures
Denosumab is a potent monoclonal antibody which inactivates
the RANK ligand. Inactivation of RANK ligand leads to the
inhibition of osteoclast activity and maturation which decreases
bone resorption. Denosumab is a potent antiresorptive that has been shown to dramatically suppress bone turnover markers, maintain bone mineral density, and prevent fractures
IWO Meeting 1 November 2023 - Stopping with Denosumab and Romosozumab, basic mechanisms and clinical aspects door Prof. dr. S. Ferrari, Geneva, Switzerland. (Engelstalige lezing)
IWO Meeting 16 November 2022 - ASBMR young talent: Silvia Storoni (Amsterdam): Prevalence and Hospital Admissions in Patients With Osteogenesis Imperfecta in The Netherlands: A Nationwide Registry Study
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Identification and nursing management of congenital malformations .pptx
IWO Meeting 17 November 2021 - Prof. Dr. Willem F Lems
1. • Module 7 Medicatie ter preventie van fracturen bij glucocorticoïden
• Uitgangsvraag
• Wanneer en welke medicatie ter preventie van fracturen is bij gebruik van glucocorticoïd
geïndiceerd?
• Prof Dr Willem F Lems 17-11-2021
• Amsterdam University medical centre, location VUmc
• Department of Rheumatology, (EULAR Center of Excellence),
• Amsterdam, the Netherlands
Copyright
Prof. Dr. Willem F Lems
2. Disclosure:
Willem F. Lems, MD
Company
Speaking Fees/
Advisory Boards
Amgen, Eli Lilly, Merck, Curaphar, Galapagos, Pfizer.
Copyright
Prof. Dr. Willem F Lems
3. Risk factors for osteoporosis and fractures
in patients with rheumatic diseases
Primary
Osteoporosis
Secondary
Osteoporosis
Copyright
Prof. Dr. Willem F Lems
4. Glucocorticoids and vertebral fracture
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0
van Staa TP et al. JBMR 2000;15:993-1000
Women
Men
High dose
Medium dose
Low dose
Control
Incidence (%)
<35 40 50 60 70 80 >85
<35 40 50 60 70 80 >85
Age (yrs)
Copyright
Prof. Dr. Willem F Lems
5. 0.0
0.5
1.0
1.5
2.0
PMO GIO PMO GIO
RR
N = 9,681 987 14,551 500
Vertebral fracture Non-vertebral fracture
RR= 0.58 0.48 0.81 0.79
Oral bisphosphonates In postmenopausal women and GIOP
From Kanis et al, Health Tech Assess 2007;11:1-258
Copyright
Prof. Dr. Willem F Lems
6. Modern GIOP-studies
New drugs are not tested against placebo, but against an active
comparator!
Copyright
Prof. Dr. Willem F Lems
8. Saag K et al. AR 2009, New Engl J Med 2007
ModernGIOP-studies
Copyright
Prof. Dr. Willem F Lems
9. % of patients with fractures:
teriparatide versus alendronate in GIOP
alendronate
teriparatide
p=0,004
p=0.007
Saag A & R 2009, New Engl J Med 2007
Copyright
Prof. Dr. Willem F Lems
10. Effect of Denosumab Compared With Risedronate in
Glucocorticoid-treated Individuals: Results From the 12-month
Primary Analysis of a Randomized, Double-blind, Active-controlled Study
K Saag1, RB Wagman2, P Geusens3, J Adachi4, O Messina5,R Emkey6,
R Chapurlat7, NS Daizadeh2, N Pannacciulli2,WF Lems8
1University of Alabama, Birmingham, AL, USA; 2Amgen Inc., Thousand Oaks, CA, USA;
3Maastricht University, Maastricht, The Netherlands; 4McMaster
EULAR; Madrid, Spain; June 14, 2017; Presentation #OP0010
Accepted for publication Lancet Endocrinology on 27 02 2018
Copyright
Prof. Dr. Willem F Lems
11. -0,5
1
2,5
4
5,5
-0,5
1
2,5
4
5,5
Lumbar Spine BMD Percentage Change From Baseline
at Months 6 and 12
Glucocorticoid-continuing (GC-C) Glucocorticoid-initiating (GC-I)
BL 6 12 BL 6 12
BMD
Percentage
Change
From
Baseline
BMD
Percentage
Change
From
Baseline
Study Month Study Month
227 211
224 209
128 126
127 119
Risedronate n=
Denosumab n=
n = Number of subjects with observed values at baseline and the time point of interest; *p ≤ 0.002
*
* *
*
Risedronate Denosumab
Copyright
Prof. Dr. Willem F Lems
12. -0,2
0,6
1,4
2,2
3,0
-0,5
0,4
1,3
2,1
3,0
Total Hip BMD Percentage Change From Baseline at
Month 12
* *
BMD
Percentage
Change
From
Baseline
BMD
Percentage
Change
From
Baseline
n = Number of subjects with observed values at baseline and the time point of interest; *p ≤ 0.001
BL 6 BL 6 12
Study Month Study Month
Risedronate n=
Denosumab n=
12
215
217
128
119
Glucocorticoid-continuing (GC-C) Glucocorticoid-initiating (GC-I)
Risedronate Denosumab
Copyright
Prof. Dr. Willem F Lems
14. 14
Guidelines for Management of Glucocorticoid-Induced Osteoporosis.
Weinstein RS. N
Copyright
Prof. Dr. Willem F Lems
15. • GIOP is most common form of secondary osteoporosis;
• GCs are associated with elevated vertebral and non-vertebral fracture risk;
• Effective antiosteoporotic drug treatment is available!
• Are GC-treated patients optimal protected with anti-osteoporotic drugs?
• Urgent Need for Guidelines that help Clinicians to Prevent Fractures in their GC-treated
patients: but are all guidelines the same/comparable?
Copyright
Prof. Dr. Willem F Lems
17. % of individuals > 50 years, using > 7.5 mg prednsione per day
and bone sparing drugs, in the Netherlands: around 30%!
Copyright
Prof. Dr. Willem F Lems
21. Really New!
• Overweeg direct te starten met parenterale medicatie (denosumab,
teriparatide of zoledroninezuur) bij:
• patiënten van 50 jaar en ouder die behandeld worden met ≥ 7,5 mg
prednison per dag gedurende 3 maanden en
• die een zeer hoog fractuurrisico hebben, bijvoorbeeld in geval van
een of meerdere risicofactoren:
– leeftijd ≥ 75 jaar;
– een recente (< 2 jaar) niet-wervelfractuur;
– een wervelfractuur graad 2, bevestigd met beeldvorming (minimaal ≥ 25%
hoogteverlies)
– een lage T-score (≤-2.0) in heup en/of wervelkolom;
– hoge dosis glucocorticoïden (≥ 15 mg per dag gedurende tenminste 3 maanden);
– een ernstige activiteit van de onderliggende ziekte.
Copyright
Prof. Dr. Willem F Lems
22. Alendronaat, Risedronaat
Zolendronaat, Denosumab of
Teriparatide
≥ 40jr
Prednison: ≥ 2,5 mg
en < 7,5 mg
neen
Wervelfractuur ≥ gr2
en/of BMD* ≤ -2
ja
Geef leefstijl en valpreventie adviezen, start zo nodig Ca/D3
Lab
DXA+VFA
Prednison < -2,5
mg (elke leeftijd)
< 40jr
Prednison: ≥ 7,5 mg
40-50 jr
Recente fractuur (≤ 1 jaar) of
klinische WF (≥ gr 2)
≥ 50jr
Indien :
Leeftijd ≥ 75 jaar of
Recente fractuur of≥ gr 2 of
T-score ≤-2 of ≥
≥ 15 mg per dag of
Hoge ziekte-activiteit
Bijwerkingen
of
Therapie falen
Prednison: stop
DXA+VFA
Indien:
T≤-2.5 of
Wervelfractuur ≥ gr 2 of
Fractuur afgelopen 2 jr
Therapie door
Behandelschema patienten met Glucocorticoiden ≥ 3 maanden
Therapie
Therapie 2e
lijn
Van wervelkolom of totale heup of heuphals
neen ja
Copyright
Prof. Dr. Willem F Lems
23. • Guidelines differ in GC dose/duration and BMD-treshold before
starting anti-osteoporotic treatment;
• Implementation of guidelines might be inhibited by complexity
and accelerated by simplicity and the use of clinically relevant
features.
• Life-Style factores, including exercise therapy, is important!
• In GC-treated patients with high fracture risk, starting with
second-line drugs (teriparatide, zoledronic acid or denosumab)
might be attractive.
Copyright
Prof. Dr. Willem F Lems
24. Learning goals 1. In 50+ patienten met ≥7,5 mg prednison per dag gedurende
tenminste 3 maanden, direct starten met anti-osteoporose
medicatie/orale bisfosfonaten (zonder DXA/VFA);
2. Idem, als er hoog fractuurrisico is: direct starten met
denosumab, teriparatide of zoledronaat;
3. 40-50 jaar en ≥7,5 mg prednison gedurende tenminste 3
maanden, en recente niet-wervelfractuur of klinische
wervelfractuur: direct starten orale bisfosfonaten (zonder
DXA/VFA)
4. Overige: 40+ en ≥2,5 mg prednison diagnostische DXA,
behandelen als T< -2 of wervelfractuur graad 2;
5. Stop prednison: DXA/VFA en een T-score > -2,5,
geen wervelfractuur en geen recente niet-wervelfractuur.
Content
Er is nog steeds onderbehandeling van GIOP, dit vraagt om actie van de
voorschrijvend arts!
Copyright
Prof. Dr. Willem F Lems
25. Thank you for your attention! Questions?? Or
wf.lems@amsterdamumc.nl
Copyright
Prof. Dr. Willem F Lems
26. IWO 25 jaar (1996-2021)
1995
Copyright
Prof. Dr. Willem F Lems
27. 27
“Not only Glucocorticoids, but also the underlying disease might
have a negative effect on bone strength! (drug/disease confounding)
RA Disease Activity Bone Strength
Glucocorticoids
Courtesy of Maarten Boers
Secondary Osteoporosis: RA, SLE, Vasculitis, COPD, Inflammatory Bowel
Disease, etc
Copyright
Prof. Dr. Willem F Lems